- Home
- SGRY vs IDYA Comparison
SGRY vs IDYA Comparison
Compare SGRY & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRY
- IDYA
- Stock Information
- Founded
- SGRY 2004
- IDYA 2015
- Country
- SGRY United States
- IDYA United States
- Employees
- SGRY N/A
- IDYA N/A
- Industry
- SGRY Hospital/Nursing Management
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- SGRY Health Care
- IDYA Health Care
- Exchange
- SGRY Nasdaq
- IDYA Nasdaq
- Market Cap
- SGRY 2.8B
- IDYA 2.3B
- IPO Year
- SGRY 2015
- IDYA 2019
- Fundamental
- Price
- SGRY $21.87
- IDYA $24.61
- Analyst Decision
- SGRY Buy
- IDYA Buy
- Analyst Count
- SGRY 8
- IDYA 14
- Target Price
- SGRY $33.71
- IDYA $47.75
- AVG Volume (30 Days)
- SGRY 1.3M
- IDYA 1.2M
- Earning Date
- SGRY 11-11-2025
- IDYA 11-03-2025
- Dividend Yield
- SGRY N/A
- IDYA N/A
- EPS Growth
- SGRY N/A
- IDYA N/A
- EPS
- SGRY N/A
- IDYA N/A
- Revenue
- SGRY $3,237,000,000.00
- IDYA $7,000,000.00
- Revenue This Year
- SGRY $9.91
- IDYA $62.30
- Revenue Next Year
- SGRY $9.70
- IDYA $285.58
- P/E Ratio
- SGRY N/A
- IDYA N/A
- Revenue Growth
- SGRY 12.05
- IDYA N/A
- 52 Week Low
- SGRY $18.87
- IDYA $13.45
- 52 Week High
- SGRY $33.90
- IDYA $37.80
- Technical
- Relative Strength Index (RSI)
- SGRY 44.28
- IDYA 50.16
- Support Level
- SGRY $21.26
- IDYA $23.23
- Resistance Level
- SGRY $22.21
- IDYA $27.69
- Average True Range (ATR)
- SGRY 0.51
- IDYA 1.35
- MACD
- SGRY -0.13
- IDYA -0.13
- Stochastic Oscillator
- SGRY 25.47
- IDYA 30.94
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.